Lamivudine Tablets

Lamivudine is a nucleoside antiviral drug. It has a strong inhibitory effect on hepatitis B virus (HBV) in vitro and in experimentally infected animals. Lamivudine can be metabolized in HBV-infected cells and normal cells to produce lamivudine triphosphate, which is the active form of lamivudine and is both an inhibitor of HBV polymerase and a substrate of this polymerase. Lamivudine triphosphate penetrates into the viral DNA chain and blocks the synthesis of viral DNA. Lamivudine triphosphate does not interfere with the metabolism of deoxynucleosides in normal cells. It has a weak inhibitory effect on mammalian DNA polymerase a and b and has almost no effect on the DNA content of mammalian cells. Lamivudine has no obvious toxicity to the structure, DNA content and function of mitochondria. The results of serum HBVDNA detection in most hepatitis B patients showed that lamivudine can rapidly inhibit HBV replication, and its inhibitory effect lasts throughout the treatment process, while reducing serum aminotransferase to normal.

The main ingredient of this product is lamivudine

This product is a film-coated tablet, which appears white after removing the film coating.

Lamivudine tablets are indicated for the treatment of adult patients with chronic hepatitis B with compensated liver function and elevated alanine aminotransferase [ALT] and viral activity.

Oral administration: adults 0.1g at a time, once a day.

Common adverse reactions include upper respiratory tract infection-like symptoms, headache, nausea, malaise, abdominal pain and diarrhea. The symptoms are generally mild and can be relieved on their own.

It is contraindicated for patients who are allergic to lamivudine or any other ingredient in the preparation.

Precautions for children: There is no efficacy and safety data for patients under 16 years old. Precautions for pregnancy and lactation: 1. Patients within 3 months of pregnancy should not use this product. Patients who are more than 3 months pregnant should weigh the pros and cons when using this product. 2. Breastfeeding women should stop breastfeeding when taking this product. Precautions for the elderly: For elderly patients whose renal excretion function decreases due to age, there is no significant change in lamivudine metabolism, and it will only be affected when the creatinine clearance rate is 30ml/min.

1. When lamivudine is used simultaneously with drugs with the same excretion mechanism (such as trimethoprim, sulfamethoxazole), the blood concentration of lamivudine can increase by 40%, which has no clinical significance, but patients with renal impairment should pay attention. 2. When used in combination with zidovudine, the latter's peak blood concentration (Cmax) can be increased, but it does not affect the elimination and area under the drug-time curve of the two.

Store below 30°C.

0.1 g

24 months

Yaopharma Co., Ltd.

• Founded in:

  1997-07-21

• Address:

  No. 100, Xingguang Avenue, Renhe Town, Yubei District, Chongqing

• Tax NO.:

  91500000202851807X

• Registered Funds:

  196.54 million yuan

• Website:

  Log in to view

• Email:

  Log in to view